Pathologic response as an early endpoint for survival following neoadjuvant androgen deprivation therapy plus abiraterone acetate for metastatic prostate cancer
For patients with LAPCa or mPCa after neoadjuvant AA plus ADT, PSA nadir help predict tumor downstaging or pCR. The patients with tumor downstaging, pCR, or PSA nadir < 0.2 ng/ml have a longer progression time to CRPC.
Authors
- Lijun Mao
- Huiqin Lu (ORCID: https://orcid.org/0000-0002-6446-6702)
- Fukun Wei
- Jie Wang (ORCID: https://orcid.org/0000-0002-5852-9754)
- Zhen Song
- Kaichen Zhou (ORCID: https://orcid.org/0009-0008-7890-8736)
Institutions
- Xuzhou Medical College (CN)
Publication Details
- Journal
- European journal of medical research
- Published
- 2025-04-04
- DOI
- https://doi.org/10.1186/s40001-025-02521-7
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Xuzhou Science and Technology Program